Trending Now
Precision BioSciences Inc. (NASDAQ:DTIL) Receives Fast Track Designation For PBCAR269A For...
Precision BioSciences Inc. (NASDAQ:DTIL) has announced that it has received Fast Track Designation from the FDA for PBCAR269A in treating refractory/relapsed multiple myeloma.
Fast Track...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
ADMA Biologics Inc (NASDAQ: ADMA) Announces a Presentation For ASCENIV
ADMA Biologics Inc (NASDAQ: ADMA) announced there would be a presentation on respiratory viral infections and its ASCENIV therapy. The FDA has approved ASCENIV,...
MAKE IT MODERN
LATEST REVIEWS
Precigen Inc (NASDAQ: PGEN) Announces Definitive Agreement For The Sale Of...
Precigen Inc (NASDAQ: PGEN) has announced a definitive agreement to sell its wholly-owned animal reproductive technology subsidiary Trans Ova Genetics L.C. to URUS for...
MAKE IT MODERN
PERFORMANCE TRAINING
MHRA Authorizes Sorrento Therapeutics Inc (NASDAQ: SRNE) To Conduct Phase 2 Efficacy Clinical Study...
The UK’s regulatory agency – MHRA (Medicines and Healthcare products Regulatory Agency), authorized Sorrento Therapeutics Inc (NASDAQ: SRNE) to commence phase 2 efficacy trial...
atai Life Sciences ‘(NASDAQ: ATAI) Philanthropic initiative Donates $500,000 To Multidisciplinary Association for Psychedelics
atai Life Sciences ‘(NASDAQ: ATAI) atai Impact, a philanthropic initiative, has announced the award of $500,000 to the Multidisciplinary Association for Psychedelics (MAPS). The...
Global Blood Therapeutics Inc. (NASDAQ:GBT) Reports $36.9 Million In Net Sales From Oxbryta® In...
Global Blood Therapeutics Inc. (NASDAQ:GBT) has announced its third quarter ended September 30 results and reported its corporate updates.
GBT launched Oxbryta for SCD patients...
BioCryst Pharmaceutical Inc. (NASDAQ:BCRX) Announced Data For BCX9930 Clinical Trial In Treatment-Naïve PNH
BioCryst Pharmaceutical Inc. (NASDAQ:BCRX) has released new data from the treatment-naïve paroxysmal nocturnal hemoglobinuria (PNH)patients. This is for the patients who receive doses via...
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Enters Commercialization Agreement with Otsuka Pharmaceuticals for Voclosporin
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) has announced the signing of a collaboration and license agreement with Otsuka Pharmaceutical Co. Ltd. The agreement is...
MAKE IT MODERN
